An interventional study of toothbrushing and flossing in Gingivitis, sponsored by Università degli Studi di Ferrara. Recruiting at 1 site in Italy. Open to participants aged 12 Years to 14 Years. Per ClinicalTrials.gov, last updated 2025-03-25.
Sponsored by Università degli Studi di Ferrara · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies in Gingivitis with a site in Italy — 9 open to participants now, 10 under way, 1 of them phase 3. Gingivitis · Italy.
Among the 32 studies in Gingivitis with a site in Italy, this one is the 4th largest by planned enrollment of the 28 interventional ones that give a count, is one of 8 that started in 2025, is one of 22 with no phase, and was the 21st registered.
635 studies on the registry are indexed under Gingivitis; 109 are open to participants now.
Browse Gingivitis studies →9 of the 32 studies in Gingivitis with a site in Italy are open now. Recruiting first, the newest first:
Colgate Palmolive · Sites in Italy
Ages 18–70 · Healthy volunteers
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University · Sites in Italy, China, United Kingdom
Ages 18+ · Healthy volunteers
University of Pavia · Sites in Italy
Ages 18–45 · Women only
University of Pavia · Sites in Italy
Ages 18+ · Women only
University of Catania · Sites in Italy
Ages 18–70 · Healthy volunteers
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 54 Gingivitis studies recruiting now, 16 (30%) set no upper age limit and 36 (67%) stop at 75 or younger; 11 take children under 18; 36 take healthy volunteers.
This study: 12 Years to 14 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 8 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is above the median of 66 across 512 interventional studies indexed under Gingivitis.
Median enrollment 55 across the 28 interventional studies, 95 across the 4 observational. Of the 18 that completed or were terminated, 1 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 32 have an industry lead sponsor. The 10 most frequent:
Università degli Studi di Ferrara is the lead sponsor of 65 studies on the registry; 10 are open to participants now.
Università degli Studi di Ferrara has 1 study filed under Gingivitis — fewer than ten, so there is no comparison to draw.
1 of the studies in Gingivitis with a site in Italy that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07842991Phase 3Colgate PalmoliveClinical Evaluation of a Toothpaste for Dental Plaque Reduction and Prevention of Gum Problems | 2027-01 |
Add it to your calendar (.ics) → With an account.
Among the 32 studies in Gingivitis with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to evaluate if the adjunctive use of an amine and zinc lactate - containing mouthrinse may give significant benefits in the home-based treatment of plaque-induced gingivitis in adolescents. The study is based on the following hypothesis: the periodontal conditions of participants affected by gingivitis will significantly benefit from the implementation of the self-performed plaque control regimen (consisting of manual toothbrush and amine and zinc lactate toothpaste) with an amine and zinc lactate - containing mouthrinse. The benefit is expected to become manifest in terms of impact on clinical periodontal parameters, ecology of the subgingival environment, patient-reported outcomes and oral-health-related quality of life. In other words, gingivitis participants implementing their self-performed oral hygiene with the investigated mouthrinse are expected to assume a closer profile (based on the outcomes listed above) to periodontally healthy subjects when compared to gingivitis participants not using the investigated mouthrinse.
One hundred fifty participants (100 adolescents with gingivitis and 50 periodontally healthy adolescents) will be selected for the study. Gingivitis patients will be asked to participate in 5 observation intervals: screening visit, study baseline, and 3 follow-up visits (3 weeks, 3 months, 6 months), while periodontally healthy controls will conclude their participation in the study within the baseline visit.
According to the randomization list, at baseline gingivitis patients will receive one of the following home-based oral hygiene regimen:
At baseline, both gingivitis patients and periodontally healthy subjects will undergo:
The 6-month proportion of periodontally healthy participants in each gingivitis group (Gt and Gc) will be regarded as the primary outcome of the study. Changes in clinical parameters, subgingival microbial community profile, and scores related to patient-reported outcomes will be regarded as the secondary outcome measures.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Gingivitis patients assigned to test intervention will use: manual toothbrush (meridol) and dental floss (meridol) associated with amine and zinc lactate - containing toothpaste (meridol Gum Protection) and amine and zinc lactate - containing mouthrinse (meridol Gum Protection)
Other: toothbrushing · Other: flossing · Device: Toothpaste Product · Device: Mouthrinse
Gingivitis patients assigned to control intervention will use: manual toothbrush (meridol) and dental floss (meridol) associated with amine and zinc lactate - containing toothpaste (meridol Gum Protection)
Other: toothbrushing · Other: flossing · Device: Toothpaste Product
Periodontally healthy subjects will be compared for baseline assessments with gingivitis patients of the other two arms. However, periodontally subjects will conclude their participation in the study within the baseline visit after receiving devices and instructions related to the control intervention.
Other: toothbrushing · Other: flossing · Device: Toothpaste Product
manual toothbrush (meridol)
dental floss (meridol)
amine and zinc lactate - containing toothpaste (meridol Gum Protection)
amine and zinc lactate - containing mouthrinse (meridol Gum Protection)
6-month proportion of periodontally healthy participants
At 6 months, the proportion (range: 0%-100%) of cases of periodontal health (as diagnosed according to the case definition of the 2017 World Workshop) will be evaluated and compared between Gt and Gc groups.
Time frame: 6 months
Gingival Index (GI)
GI (without the BoP component) will be assessed on a scale from 0 (no clinically detectable inflammation) to 3 (severe inflammation with spontaneous bleeding) at the mesio-buccal aspects of 6 index teeth (i.e., 1.6, 2.1, 2.4, 3.6, 4.1, 4.4). Gt and Gc groups will be compared for the 3-week, 3-month and 6-month changes in Gi.
Time frame: 3 weeks, 3 months, 6 months
Plaque score
Plaque score will be evaluated as present (0) or absent (1) at 6 sites (mesio-buccal, buccal, disto- buccal, mesio-lingual, lingual, disto-lingual) of each tooth. Gt and Gc groups will be compared for the 3-week, 3-month and 6-month changes in the full-mouth proportion of sites with plaque.
Time frame: 3 weeks, 3 months, 6 months
Bleeding on probing (BoP)
BoP will be evaluated as present/absent using a UNC15 probe (Hu-Friedy Italy s.r.l., Milano, Italy) at 6 sites (mesio-buccal, buccal, disto-buccal, mesio- lingual, lingual, disto-lingual) of each tooth. Gt and Gc groups will be compared for the 3-week, 3-month and 6-month changes in the full-mouth prevalence of BoP (range: 0%-100%).
Time frame: 3 weeks, 3 months, 6 months
Probing depth (PD)
PD will be measured in mm using a UNC15 probe (Hu-Friedy Italy s.r.l., Milano, Italy) at 6 sites (mesio-buccal, buccal, disto-buccal, mesio- lingual, lingual, disto-lingual) of each tooth. Gt and Gc groups will be compared for the 3-week, 3-month and 6-month changes in PD.
Time frame: 3 weeks, 3 months, 6 months
Clinical attachment level (CAL)
CAL will be measured in mm using a UNC15 probe (Hu-Friedy Italy s.r.l., Milano, Italy) at 6 sites (mesio-buccal, buccal, disto-buccal, mesio- lingual, lingual, disto-lingual) of each tooth. Gt and Gc groups will be compared for the 3-week, 3-month and 6-month changes in CAL.
Time frame: 3 weeks, 3 months, 6 months
Plaque sampling and microbiological analysis
Plaque sampling will be performed with sterile Mini Five Gracey curettes (Hu-Friedy Italy s.r.l., Milano, Italy) from the subgingival area at the mesio- buccal aspects of 6 index teeth (Manual of Procedures for Human Microbiome Project - Core Microbiome Sampling Protocol Version Number: 12.0; 29 Jul 2010). The microbial composition of each sample will be analyzed by a real-time quantitative PCR (qPCR) microarray, providing profiling of microorganisms usually found in dental plaque (Microbial DNA qPCR Array for Oral Disease) (Qiagen, Hilden, Germany). Array assays are designed using the 16S rRNA gene as the target gene and individual primers and hydrolysis-probe detection, increasing specificity of each assay. Amplification will be carried out in a Quant Studio 5 thermocycler (Thermo Fisher Scientific, Milan, Italy), providing simultaneous detection and quantification of 93 different microbial species, including putative and known periodontopathogens.
Time frame: 3 weeks, 3 months, 6 months
Patient satisfaction with the use of the oral hygiene regimen
At 6 months, the participant will be asked to state his/her degree of satisfaction with the use of the oral hygiene regimen used during the experimental phase. Satisfaction will be classified as follows: 0- excellent; 1-good; 2- acceptable; 3- poor. The participant will also be asked about possible side effects and complaints related to the use of the assigned products. This evaluation will be performed without the presence of the examiners to enable the participant to give his/her honest opinion.
Time frame: 6 months
Oral-health related quality of life (OHrQoL)
At baseline and 6 months, participants will be instructed to fill the Child Perceptions Questionnaire for 11- to 14 year-old Children (CPQ11-14). The questionnaire will be filled by the participant under the supervision of the examiner. The assessment is developed through 37 questions distributed in 4 sections, which refer to: oral symptoms, functional limitations, emotions related to the condition of the oral cavity, and what role this has in social relationships. Each question will be rated according to the following scale: never (0); once or twice (1); sometimes (2); often (3); every day or almost every day (4). The total score will be obtained as the algebraic sum of the single scores, and will range from 0 (indicating no impact of the oral health condition on the quality of life) to 148 (indicating maximum impact of the oral condition on the quality of life).
Time frame: Baseline, 6 months
Adverse events (AEs)
Adverse events will be recorded on a dedicated form, and major adverse events will be immediately communicated to the Operative Unite of Legal Medicine, University - Hospital of Ferrara, Italy.
Time frame: 6 months
Plan to share: No — Biological samples (subgingival plaque) will be analyzed at the Section of Microbiology, University of Ferrara, Italy. However, the analysis will be conducted in a blinded fashion (no information related to patient identity and observation interval will be provided for each sample to be analyzed).
Started Jan 2025 (actual). Primary completion is estimated for Jul 2026, 18 months after the start.
Of 207 non-industry interventional studies with no phase under Gingivitis, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 17. This study's planned 18 months is above that.
Counting every sponsor, half of 260 studies reached it within 7 months; a quarter within 3 and three quarters within 15.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Università degli Studi di Ferrara